102 related articles for article (PubMed ID: 25394558)
1. Expression and anticancer activity analysis of recombinant human uPA1‑43-melittin.
Su M; Chang W; Cui M; Lin Y; Wu S; Xu T
Int J Oncol; 2015 Feb; 46(2):619-26. PubMed ID: 25394558
[TBL] [Abstract][Full Text] [Related]
2. Expression and activity analysis of a new fusion protein targeting ovarian cancer cells.
Su M; Chang W; Wang D; Cui M; Lin Y; Wu S; Xu T
Oncol Rep; 2015 Sep; 34(3):1337-44. PubMed ID: 26166362
[TBL] [Abstract][Full Text] [Related]
3. Expression and purification of recombinant ATF-mellitin, a new type fusion protein targeting ovarian cancer cells, in P. pastoris.
Su M; Chang W; Zhang K; Cui M; Wu S; Xu T
Oncol Rep; 2016 Feb; 35(2):1179-85. PubMed ID: 26718643
[TBL] [Abstract][Full Text] [Related]
4. Expression and functional characterization of a recombinant targeted toxin with an uPA cleavable linker in Pichia pastoris.
Zhu Wh; Sun Mn; Wang Ys; Sun DJ; Zhang Sx
Protein Expr Purif; 2011 Apr; 76(2):184-9. PubMed ID: 21144903
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer.
Türkmen B; Schmitt M; Schmalfeldt B; Trommler P; Hell W; Creutzburg S; Graeff H; Magdolen V
Electrophoresis; 1997 May; 18(5):686-9. PubMed ID: 9194591
[TBL] [Abstract][Full Text] [Related]
6. The anti-cancer potency and mechanism of a novel tumor-activated fused toxin, DLM.
Sun D; Sun M; Zhu W; Wang Z; Li Y; Ma J
Toxins (Basel); 2015 Feb; 7(2):423-38. PubMed ID: 25658509
[TBL] [Abstract][Full Text] [Related]
7. Preparation and functional characterization of human vascular endothelial growth factor-melittin fusion protein with analysis of the antitumor activity in vitro and in vivo.
Wang D; Hu L; Su M; Wang J; Xu T
Int J Oncol; 2015 Sep; 47(3):1160-8. PubMed ID: 26166416
[TBL] [Abstract][Full Text] [Related]
8. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
9. Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway.
Jo M; Park MH; Kollipara PS; An BJ; Song HS; Han SB; Kim JH; Song MJ; Hong JT
Toxicol Appl Pharmacol; 2012 Jan; 258(1):72-81. PubMed ID: 22027265
[TBL] [Abstract][Full Text] [Related]
10. Construction and expression of sTRAIL-melittin combining enhanced anticancer activity with antibacterial activity in Escherichia coli.
Liu H; Han Y; Fu H; Liu M; Wu J; Chen X; Zhang S; Chen Y
Appl Microbiol Biotechnol; 2013 Apr; 97(7):2877-84. PubMed ID: 23149754
[TBL] [Abstract][Full Text] [Related]
11. High-level expression, purification and study of bioactivity of fusion protein M-IL-2((88)Arg, (125)Ala) in Pichia pastoris.
Li L; Qian D; Shao G; Yan Z; Li R; Hua X; Song X; Wang B
Protein Expr Purif; 2014 Sep; 101():99-105. PubMed ID: 24955549
[TBL] [Abstract][Full Text] [Related]
12. [Cloning and expression of a gene encoding shortened LfcinB(1-15)-Melittin(5-12) hybrid peptide in Escherichia coli BL21(DE3)].
Bi C; Feng X; Shan A; Guo J
Sheng Wu Gong Cheng Xue Bao; 2009 Jul; 25(7):975-81. PubMed ID: 19835136
[TBL] [Abstract][Full Text] [Related]
13. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
14. Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase.
Ruppert C; Mahavadi P; Wygrecka M; Weaver TE; Magdolen V; Idell S; Preissner KT; Seeger W; Günther A; Markart P
Thromb Haemost; 2008 Dec; 100(6):1185-92. PubMed ID: 19132247
[TBL] [Abstract][Full Text] [Related]
15. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Kamiyama H; Zhou G; Roizman B
Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
[TBL] [Abstract][Full Text] [Related]
18. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
19. Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence.
Liang OD; Chavakis T; Linder M; Bdeir K; Kuo A; Preissner KT
Biol Chem; 2003 Feb; 384(2):229-36. PubMed ID: 12675515
[TBL] [Abstract][Full Text] [Related]
20. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
